Le Lézard
Classified in: Health
Subject: SVY

Global Immunotherapeutic Drugs Market, 2022 - Key Factors in the Trend Toward Patient Enablement and Self-Administration


DUBLIN, Oct. 23, 2018 /PRNewswire/ --

The "Immunotherapeutic Drugs, Devices & Patient Enablement Immunotherapeutic Drugs, Devices & Patient Enablement" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Immunotherapeutic Drugs, Devices & Patient Enablement: Devices, Packaging, Therapeutics, Strategies and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for self-administered injectable drugs for treating autoimmune conditions.

Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Drug Formulation & Packaging Migration Creating Self-Dosing Opportunities

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration.

Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

Immunotherapeutic Drugs, Devices & Patient Enablement - What You Will Learn

Key Topics Covered:

Executive Summary

Market Dynamics
Competitive Landscape
Biological Supply Chain Activity
FDA/EMA Immunotherapeutics Regulatory Overview
Cost per Dose and Managed Care
Biosimilars
Product Design and Enablement Factors
Ease of Use
Patient Adherence
Human Engineering/Ergonomics
Patient-centered Design
Patient Interface
Patient Preferences
Device Development and As-Supplied Packaging
Device Supplier Segment Analysis
Pre- and Post-marketing Device Evolution

Self-administered Enabling Devices
Device Selection - Stability and Materials Issues
Prefilled Syringes
Autoinjectors
Manual Injection Autoinjectors
Automatic Injection Autoinjectors
Special Feature Autoinjectors
Variable Dose Autoinjectors
Pen Injectors
Emerging Devices

Self-administered Therapeutic Autoimmune Drug Assessment

Therapeutic Market Segment Analysis & Forecasts

Market Factors
Regulatory Factors
Clinical Trial Protocols & Endpoints
Alliances and Partnerships

Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/8zbr23/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 04:00
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...



News published on and distributed by: